FDA Clears Oropharyngeal Zapper Into Class II Medical Devices
Published Date: 6/1/2026
Rule
Summary
The FDA is officially putting the oropharyngeal electrical stimulator into Class II, meaning it has special safety rules but is easier to get to patients. This change helps make sure the device is safe and effective while cutting down on red tape, so more people can benefit from this cool tech. The new rules took effect on June 1, 2026, but the classification has been in place since September 2022.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Easier approval path for future devices
FDA's De Novo classification lets this device serve as a predicate so future oropharyngeal electrical stimulators can use the 510(k) process instead of a De Novo or premarket approval, which the FDA says reduces regulatory burden. The De Novo request was received April 19, 2022, and the device was classified on September 16, 2022.
Easier access to swallowing device
The FDA classified the oropharyngeal electrical stimulator as Class II with special controls, which the agency says will enhance patients' access to the device and reduce regulatory burdens. The final order is effective June 1, 2026, and the classification was applicable on September 16, 2022.
New testing, labeling, and 510(k) duties
To fall within Class II, oropharyngeal electrical stimulators must meet special controls such as non-clinical performance testing (electrical output, mechanical integrity, oxygen safety), biocompatibility, sterility and shelf-life testing, reprocessing validation, software verification and hazard analysis, electromagnetic compatibility, training programs, usability testing, and labeling that includes shelf life. FDA also states the device is subject to premarket notification under section 510(k).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17812, Determination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that NAMENDA (memantine hydrochloride) tablets, 5 milligrams (mg) and 10 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as the ANDAs meet relevant legal and regulatory requirements.
2026-17659, Rahim Shafa; Denial of Hearing; Final Debarment Order
The Food and Drug Administration (FDA or Agency) is denying a request for a hearing submitted by Rahim Shafa (Dr. Shafa) and is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Dr. Shafa from providing services in any capacity to a person that has an approved or pending drug product application and debarring Dr. Shafa for 20 years from importing or offering for import any drug into the United States. FDA bases this order on the findings that Dr. Shafa was convicted of multiple felonies under Federal law that relate to the regulation of any drug product under the FD&C Act and the importation into the United States of any drug or controlled substance under the FD&C Act. FDA provided notice to Dr. Shafa of the proposed debarment and an opportunity to request a hearing. Dr. Shafa submitted a request for a hearing but failed to file with the Agency information and analyses sufficient to create a basis for a hearing.
2026-17676, Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act and Associated Fees
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection pertaining to the registration of human drug compounding outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and associated fees.
Previous / Next Documents
Previous: 2026-10891, Atlantic Highly Migratory Species; Atlantic Bluefin Tuna Fisheries; Harpoon Category Retention Limit Adjustment
Starting June 1, 2026, fishermen using harpoons to catch Atlantic bluefin tuna can only keep up to 5 big tuna per day instead of 10. This rule helps protect tuna populations and lasts until November 15, 2026, unless changed earlier. It affects all vessels with Harpoon category permits and aims to balance fishing fun with smart conservation.
Next: 2026-10895, Standard Instrument Approach Procedures, and Takeoff Minimums and Obstacle Departure Procedures; Miscellaneous Amendments
Starting June 1, 2026, the FAA is updating how pilots approach and take off from certain airports to keep flights safe and smooth. These changes affect pilots and airports by adjusting flight paths and rules based on new tech and obstacles. No big costs here—just smarter, safer skies for everyone flying under instrument rules!